Apr 15, 2016

Posted by in Biotech Stocks | 0 Comments

Trader’s Watch List: Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Amgen, Inc (NASDAQ:AMGN)

Trader’s Watch List: Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Amgen, Inc (NASDAQ:AMGN)

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) surged +1.91% and ended at $8.52. The total traded volume was 1.05 million shares and market capitalization arrived at $1.19 billion. The stock has a 52-week high price of $11.05 and its 52-week low was recorded at $5.57, while during last trade its minimum price was $8.18 and it gained the highest price of $8.56.

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) on February 11, 2016 announced the initiation of a phase 1 study with ACH-4471, the Company’s first orally-administered, highly potent and specific small molecule that has been shown to inhibit complement factor D. The phase 1 study is being conducted in healthy volunteers and is evaluating single ascending doses of ACH-4471 to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD). The Company expects to report interim clinical data from this study during the second quarter of 2016.

The initial phase 1 trial is a randomized, placebo-controlled, single-ascending dose study of ACH-4471 administered to healthy volunteers. Approximately 28 subjects are expected to be enrolled. The primary endpoint for the trial is evaluation of safety and tolerability. Secondary endpoints include assessments of PK, PD, and evaluation of alternative pathway inhibition in ex vivo laboratory assessments of blood samples from subjects in order to establish a PK/PD relationship for ACH-4471. Interim study results are anticipated during the second quarter of 2016. In addition, a second phase 1 study evaluating multiple-ascending doses in healthy volunteers is expected to be initiated in the second quarter of 2016 with interim results anticipated during the third quarter of 2016.

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) reported the increase of +7.19% to close at $27.87 with the overall traded volume of 1.16 million shares. Its market capitalization on last close reached to $1.47 billion. The company has the total of 49.08 million outstanding shares. Its intraday-low price was $25.91 and its hit its day’s highest price at $28.14.

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) on April 12, 2016 announced the closing of its previously announced public offering of common stock, including 806,451 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. Gross proceeds from the offering of an aggregate of 6,182,795 shares at a public offering price of $23.25 per share, before underwriting discounts and commissions and offering expenses, were approximately $143.8 million.

Amgen, Inc (NASDAQ:AMGN) moved up +0.04% to settle at $160.12. Its total traded volume during last trading session was 2.41 million shares. The overall market worth of this company is about $120.14 billion. The 52 week range of the stock remained $130.09 – $181.81, while its day’s lowest price was $159.37 and its hit its day’s highest price at $160.77. The beta of this stock currently stands at 0.82.

Amgen, Inc (NASDAQ:AMGN) on April 3, 2016 announced new detailed data from the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha® (evolocumab) in patients with high cholesterol who cannot tolerate statins. The study showed that in patients with reproducible statin intolerance due to muscle-related side effects (MRSE), the use of Repatha compared to ezetimibe resulted in a significantly greater reduction in low-density lipoprotein cholesterol (LDL-C) after 24 weeks. These data were presented at a Late-Breaking Clinical Trial session at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) and simultaneously published in the Journal of the American Medical Association.

The GAUSS-3 study built upon knowledge gained from the GAUSS-1 and GAUSS-2 studies, which used patient-reported incidence of statin-related side effects. GAUSS-3 employed a rigorous active statin rechallenge in patients with history of intolerance to two or more statins to determine a patient population that experienced MRSE on statin therapy but not on placebo. Despite the short, 10-week rechallenge, more than 40 percent of patients rechallenged with atorvastatin developed intolerable muscle side effects to atorvastatin and not placebo.


Comments are closed.